DoW Duchenne Muscular Dystrophy, Idea Development Award
About
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals. Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories: • The Established Investigator category is for independent investigators at all academic levels, or equivalent • The New Investigator – Early-Stage category is for independent investigators early in their careers (i. e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators. • The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bri.
The DoW Duchenne Muscular Dystrophy Idea Development Award (IDA) is a competitive research grant designed for investigators seeking to advance understanding and treatment of Duchenne muscular dystrophy (DMD). This FY2026 program supports early-stage, high-risk/high-reward research projects with strong scientific rationale and testable hypotheses that show potential for impactful discoveries. The award is particularly valuable for researchers investigating therapies across the full DMD lifespan, including infants, toddlers, and nonambulatory individuals. The program welcomes three categories of investigators: Established Investigators at any academic level, New Investigators in the early stages of their careers (within 10 years of first faculty appointment), and Investigators Transitioning into DMD research from other fields. If you're a researcher with innovative ideas that could accelerate progress in DMD treatment and outcomes, this award provides an excellent opportunity to develop and test novel approaches with dedicated federal funding support.
Funding Facts
● Applications openDeadline
September 18, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Amount varies by cycle
Deadline
2026-09-18
Grant Type
federal
Application Cycle
Annual (FY2026 deadline: September 18, 2026)
Best For
Research investigators (established, early-stage, and transitioning) conducting high-risk/high-reward DMD research
Frequently Asked Questions
Who is eligible for DoW Duchenne Muscular Dystrophy, Idea Development Award?
The award supports three categories of independent investigators: Established Investigators at all academic levels; New Investigators—Early-Stage within 10 years of their first faculty appointment; and New Investigators—Transitioning from other research areas into DMD. For complete eligibility requirements and institutional sponsorship details, consult the official Department of Defense funding announcement.
How much funding does DoW Duchenne Muscular Dystrophy, Idea Development Award provide?
Specific funding amounts are not listed in available program summaries. Award amounts vary by cycle and project scope. Contact the Department of Defense or review the FY2026 DMDRP funding announcement for current budget details.
How do I apply for DoW Duchenne Muscular Dystrophy, Idea Development Award?
Applications are submitted through the Department of Defense peer review system. Proposals must include a well-formulated, testable hypothesis with strong scientific rationale. The application deadline for FY2026 is September 18, 2026. Prospective applicants should review the official DMDRP funding announcement and consult their institution's research administration office for submission procedures and required documentation.
What can DoW Duchenne Muscular Dystrophy, Idea Development Award funding be used for?
Funding supports research investigating new ideas in early-stage development with potential to yield impactful data and novel investigative approaches for DMD. The program particularly encourages research on therapies demonstrating efficacy across the full disease lifespan, from infants through nonambulatory individuals, with the goal of accelerating progress in improving outcomes for people with DMD.
Last updated: July 5, 2026